查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014811

影像導引治療系統市場：按產品、診斷影像方法、組件、治療方法、應用和最終用戶分類－2026-2032年全球市場預測

Image-guided Therapy System Market by Product, Imaging Modality, Component, Therapy Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，影像導引治療系統市場價值將達到 51.4 億美元，到 2026 年將成長至 55.3 億美元，到 2032 年將達到 86.4 億美元，複合年成長率為 7.67%。

主要市場統計數據
基準年 2025 51.4億美元
預計年份：2026年 55.3億美元
預測年份 2032 86.4億美元
複合年成長率 (%) 7.67%

全面概述了不斷發展的影像引導治療趨勢，其中臨床準確性、整合平台和價值主導的採購正在重新定義部署模式。

影像導引治療系統市場正處於一個轉折點，臨床需求、技術成熟度以及支付方和醫療服務提供者的期望在此交匯，共同推動著更快、更安全、更經濟高效的治療方法的出現。醫院和專科醫療機構正從對成像硬體的一次性投資轉向整合先進成像模式、即時導航和軟體主導的工作流程控制的整合解決方案。這項轉變的驅動力來自臨床醫師對術中精準度的更高要求、管理者對處理能力和可預測治療結果的重視，以及病患對微創治療方案的期望。

分析重塑影像引導治療系統未來和臨床部署的關鍵變革性技術、營運和供應鏈變化。

由於多種技術和市場動態的共同作用，影像引導治療領域正經歷變革性的轉變。人工智慧 (AI) 和機器學習的進步正在改善影像重建、分割和手術決策支持，使臨床醫生能夠更快、更一致地解讀多模態影像資訊。機器人技術和先進的導航系統正與放射科實驗室更加緊密地結合，使得複雜、微創手術能夠以更高的可重複性和精確度進行。

對 2025 年美國關稅變化將如何影響影像導引治療提供者的籌資策略、採購實務和業務永續營運進行詳細評估。

美國於2025年實施的政策調整對影像導引治療系統的供應鏈、採購慣例和投資決策產生了累積影響。關稅變化影響了進口成像模組和導航組件的總到岸成本，促使買家和供應商重新評估籌資策略和總擁有成本（TCO）分析。採購團隊的因應措施包括延長供應商選擇週期，並更加重視本地服務安排，以抵消進口可能帶來的延誤和成本波動。

透過詳細的細分分析，揭示模式、應用、最終用戶、產品、組件和治療方法等維度，從而製定差異化的臨床和商業策略。

細分分析突顯了影像導引治療系統評估和應用的多面向因素。以顯像模式分類，市場涵蓋錐狀射束CT、CT、透視、MRI和超音波，每種影像方式在空間解析度、軟組織對比度、輻射暴露和操作便利性之間都存在獨特的權衡，這些權衡會影響臨床選擇和手術方案設計。按應用領域分類，臨床需求涵蓋循環系統、胃腸病學、神經病學、腫瘤學、整形外科和泌尿系統，每個專科都根據解剖結構的複雜性和治療目標，提出了獨特的成像和導航要求。

戰略區域展望，展示了美洲、歐洲、中東和非洲以及亞太地區的趨勢如何影響影像引導治療系統的採購、實施和部署。

區域趨勢持續影響影像引導治療系統投資的優先順序、投資方式和部署策略。在美洲，投資動力主要集中在整合式醫療服務體系和大規模三級醫療機構，這些機構著重於混合手術室功能和完善的服務體系。同時，門診手術中心也擴大選擇性地採用微創解決方案，以提高周轉率並縮短恢復時間。此外，該地區的醫療系統越來越重視互通性、資料安全和療效評估，這要求供應商能夠支援複雜的IT整合和部署後的效能追蹤。

深入了解競爭對手的行動、以軟體為中心的策略和服務創新如何重新定義影像引導治療領域的領導地位和夥伴關係機會，從而獲得切實可行的競爭洞察。

影像導引治療領域的競爭格局日益凸顯，端到端的價值提案融合了影像硬體、導航平台和軟體主導的工作流程協調。主要企業正透過有針對性的夥伴關係、收購和共同開發契約來拓展產品組合，加速成像模式和導航系統的整合。這些措施旨在減少臨床摩擦，並為尋求互通性和擴充性解決方案的醫療系統提供更清晰的升級路徑。

就產品、臨床證據、供應鏈和商業策略提出切實可行的、有影響力的建議，使高階主管能夠加速產品推廣並實現長期成長。

產業領導企業應優先進行一系列協調一致的努力，以在影像導引治療系統領域獲得臨床和商業性優勢。首先，他們應協調產品藍圖，並在其成像模式和導航平台之間實現模組化互通性，使客戶能夠在不更換整個系統的情況下擴展功能。產品設計若能預見分階段升級，可減少採購摩擦，並擴大目標應用場景，包括醫院、門診中心和專科診所。

為了確保提供切實可行的見解，我們採用了穩健透明的調查方法，將對臨床醫生和採購負責人的初步檢驗與二次和多方面的檢驗技術相結合。

支持這些研究結果的調查方法結合了結構化的初步研究、全面的次要研究和嚴謹的三角驗證。初步研究主要包括對介入治療臨床醫生（涵蓋循環系統、神經病學、腫瘤學和整形外科等專科）、醫院和門診手術中心的採購經理以及負責實施影像和導航系統的技術經理進行詳細訪談。這些訪談提供了臨床需求、採購限制和營運績效考量的第一手觀點。

結論簡潔明了，強調整合技術、臨床和商業性策略對於在所有醫療環境中實現影像引導治療的潛力至關重要。

影像導引治療系統的未來發展方向已然清晰。臨床對精準性、營運效率和以患者為中心的治療效果的需求將持續推動整合影像、導航和軟體平台的應用。成功的供應商將具備以下條件：結合臨床證據、靈活的商業模式、穩健的供應鏈以及以用戶為中心的設計，從而降低不同醫療機構採用該系統的門檻。技術創新與不斷變化的採購行為之間的互動，要求供應商制定敏捷的策略，以平衡當前的營運需求和長期的平台發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 影像導引治療系統市場：依產品分類

  • 硬體
  • 服務
  • 軟體
    • 影像處理軟體
    • 導航軟體
    • 工作流程管理軟體

第9章 依診斷影像方法分類的影像導引治療系統市場

  • 錐狀射束CT
  • CT
  • 透視
  • MRI
  • 超音波

第10章 影像導引治療系統市場：依組件分類

  • 配件
  • 消耗品
  • 醫療影像設備
  • 導航系統

第11章 依治療方法分類的影像導引治療系統市場

  • 微創
    • 內視鏡
    • 腹腔鏡
    • 機器人手術
  • 開放性手術

第12章 影像導引治療系統市場：依應用領域分類

  • 循環系統
  • 消化系統
  • 神經病學
  • 腫瘤學
  • 整形外科
  • 泌尿系統

第13章 影像導引治療系統市場：依最終使用者分類

  • 門診手術中心
  • 醫院
  • 診斷影像中心
  • 專科診所

第14章 影像導引治療系統市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 影像導引治療系統市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 影像導引治療系統市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國影像導引治療系統市場

第18章：中國影像導引治療系統市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accuray, Inc.
  • Analogic Corporation
  • Brainlab AG
  • Canon Medical Systems Corporation
  • Cook Medical, Inc.
  • Elekta AB
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • IMRIS, Inc.
  • Johnson & Johnson
  • Konica Minolta, Inc.
  • Koninklijke Philips NV
  • Medtronic plc
  • Olympus Corporation
  • RaySearch Laboratories AB
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Smith & Nephew plc
  • Stryker Corporation
  • Terumo Corporation
  • Varian Medical Systems, Inc.
  • Ziehm Imaging GmbH
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-43127F7279B1

The Image-guided Therapy System Market was valued at USD 5.14 billion in 2025 and is projected to grow to USD 5.53 billion in 2026, with a CAGR of 7.67%, reaching USD 8.64 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.14 billion
Estimated Year [2026] USD 5.53 billion
Forecast Year [2032] USD 8.64 billion
CAGR (%) 7.67%

Comprehensive introduction to the evolving image-guided therapy landscape where clinical precision, integrated platforms, and value-driven procurement redefine adoption patterns

The landscape of image-guided therapy systems is at an inflection point where clinical need, technological maturity, and payer and provider expectations are converging to demand faster, safer, and more cost-effective interventions. Hospitals and specialty facilities are moving beyond single-point investments in imaging hardware toward integrated solutions that combine advanced imaging modalities, real-time navigation, and software-driven workflow controls. This shift is driven by clinicians' demand for greater precision during procedures, administrators' emphasis on throughput and predictable outcomes, and patient expectations for minimally traumatic care pathways.

Clinically, the advantages of enhanced visualization and navigation are clear: reduced procedure times, minimized radiation exposure in certain modalities, and improved targeting accuracy for complex anatomies. Operationally, the push for hybrid suites and interoperable platforms is transforming procurement cycles, since capital planners now evaluate systems not only on image quality but also on software extensibility, service packages, and compatibility with existing OR ecosystem investments. As a result, stakeholders across clinical, purchasing, and IT functions are increasingly engaged in technology evaluation and adoption decisions.

Regulatory scrutiny and reimbursement dynamics are shaping the pace and nature of adoption. Regulators are placing greater emphasis on post-market evidence and real-world performance, especially for systems that incorporate machine learning or autonomous functions. Meanwhile, payers and health systems are increasingly focused on value-based outcomes, requiring vendors to demonstrate how new technologies reduce complications, shorten length of stay, or improve downstream care pathways. Taken together, these forces underscore the necessity for suppliers to present robust clinical evidence, clear operational benefits, and flexible commercial models to secure adoption across diverse care settings.

Analysis of the major transformative technological, operational, and supply chain shifts reshaping the future of image-guided therapy systems and clinical adoption

The image-guided therapy sector is experiencing transformative shifts driven by several concurrent technological and market dynamics. Advances in artificial intelligence and machine learning are improving image reconstruction, segmentation, and intra-procedural decision support, enabling clinicians to interpret multimodal imaging inputs with greater speed and consistency. Robotics and enhanced navigation systems are becoming more tightly integrated with imaging suites, enabling complex minimally invasive procedures to be performed with higher reproducibility and finer control.

Concurrently, the trend toward hybrid operating environments is reshaping capital allocation priorities. Institutions are investing in combined imaging and interventional spaces that support both traditional open surgery and minimally invasive approaches, enabling rapid protocol transitions within a single suite. This has profound implications for product design: imaging equipment must be adaptable to diverse procedural workflows, imaging footprints must be optimized for OR ergonomics, and navigation systems must support cross-modality registration to ensure seamless clinical handoffs.

Service and software offerings are gaining parity with hardware as sources of differentiation. Vendors that can deliver robust image processing, navigation, and workflow management capabilities alongside hardware options are better positioned to lock in long-term clinical and commercial relationships. This shift is reinforced by clinicians' growing expectations for continuous performance improvements delivered through software updates and modular services rather than through frequent hardware replacements.

Supply chain resiliency has also emerged as a strategic priority. Geopolitical tensions, tariff changes, and component scarcity have accelerated nearshoring, multi-sourcing, and longer-term supplier partnerships. As a result, companies that can demonstrate a resilient manufacturing footprint and predictable service levels are gaining an important trust advantage among large hospital systems and integrated delivery networks. These converging dynamics are reshaping how technologies are developed, validated, marketed, and supported across the care continuum.

Detailed assessment of how 2025 United States tariff changes have altered sourcing strategies, procurement behavior, and operational resilience for image-guided therapy providers

The policy adjustments enacted in the United States during 2025 introduced cumulative effects across supply chains, procurement practices, and investment calculus for image-guided therapy systems. Tariff changes influenced the total landed cost of imported imaging modules and navigation components, prompting buyers and suppliers to re-examine sourcing strategies and total cost of ownership analyses. Procurement teams responded by lengthening vendor qualification cycles and increasing emphasis on local service capabilities to offset potential import-related delays and cost volatility.

For manufacturers reliant on globally sourced parts, increased import duties amplified the incentive to diversify suppliers and invest in regional manufacturing capabilities. Some firms accelerated capital investments in assembly and component manufacturing closer to primary end-user markets, while others negotiated supply agreements with tier-one component suppliers to secure priority allocation. These strategic responses were not instantaneous; they required careful capital planning and revisions to product roadmaps to accommodate localized production tolerances and regulatory approvals in different jurisdictions.

Clinicians and hospital administrators felt indirect impacts as well. In environments where capital approval cycles are sensitive to price swings, procurement committees deferred certain non-urgent upgrades or adopted phased acquisition approaches, prioritizing modular expansions and service contracts that smoothed cost impacts. Simultaneously, vendors adjusted commercial models by offering more flexible payment terms, extended warranties, and bundled services to reduce initial capital burden and maintain adoption momentum.

Operationally, tariff-driven pressures also affected consumables and accessories, elevating the importance of inventory management and predictable supply. Facilities that invested in inventory optimization and alternative supplier qualification reduced procedural disruptions and maintained service levels. From a strategic perspective, organizations that proactively engaged with suppliers to co-design localized supply arrangements or to qualify alternative components gained a resilience advantage, enabling them to sustain clinical throughput while navigating the policy-induced cost environment.

In-depth segmentation insights revealing modality, application, end-user, product, component, and therapy-type dimensions that drive differentiated clinical and commercial strategies

Segmentation analysis highlights the multiple dimensions through which image-guided therapy systems are evaluated and adopted. Based on imaging modality, the landscape encompasses Cone Beam CT, CT, Fluoroscopy, MRI, and Ultrasound, each offering distinct trade-offs between spatial resolution, soft-tissue contrast, radiation exposure, and intra-procedural practicality, which in turn influences clinical choice and procedural design. Based on application, clinical demand spans Cardiovascular, Gastroenterology, Neurology, Oncology, Orthopedics, and Urology, with each specialty defining unique imaging and navigation requirements tied to anatomical complexity and therapeutic objective.

Based on end user, adoption dynamics differ markedly among Ambulatory Surgical Centers, Hospitals, Imaging Centers, and Specialty Clinics, where variations in case mix, capital budgets, staffing models, and throughput targets dictate different product and service preferences. Based on product, solutions are grouped into Hardware, Services, and Software; the Software component is further studied across Image Processing Software, Navigation Software, and Workflow Management Software, reflecting the central role software plays in enhancing clinical decision support, guiding instrumentation, and streamlining peri-procedural coordination.

Based on component, inventories and procurement strategies are shaped by Accessories, Consumables, Imaging Equipment, and Navigation Systems, each carrying different life cycles, regulatory pathways, and supply chain sensitivities that affect procurement cadence and total cost management. Based on therapy type, clinical workflows bifurcate into Minimally Invasive and Open Surgery; the Minimally Invasive category is further divided into Endoscopic, Laparoscopic, and Robotic approaches, each influencing device interfaces, imaging access, and navigation precision requirements. Together, these segmentation lenses provide a multidimensional framework for understanding buyer needs, tailoring clinical evidence generation, and designing differentiated commercial propositions for each stakeholder group.

Strategic regional perspectives demonstrating how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics influence procurement, adoption, and deployment of image-guided therapy systems

Regional dynamics continue to shape where and how investments in image-guided therapy systems are prioritized and deployed. In the Americas, investment momentum is concentrated in integrated delivery systems and large tertiary hospitals that value hybrid OR capabilities and comprehensive service arrangements, while a growing number of ambulatory surgical centers are selectively adopting minimally invasive solutions that offer rapid turnover and reduced recovery times. Health systems in this region are also increasingly focused on interoperability, data security, and outcomes measurement, requiring vendors to support complex IT integrations and post-deployment performance tracking.

In Europe, the Middle East & Africa region, adoption patterns vary significantly by country and health system maturity. Advanced European markets emphasize evidence generation, regulatory compliance, and cost-effectiveness, whereas several Middle Eastern markets are accelerating capital investments in flagship medical centers and specialty clinics, prioritizing high-end imaging suites and robotic integrations. In parts of Africa, constrained capital and workforce limitations favor solutions that are rugged, serviceable, and optimized for essential care delivery, creating opportunities for modular systems and innovative service models.

Asia-Pacific presents diverse trajectories driven by rapid investments in advanced care infrastructure in several markets and strong manufacturing capabilities in others. Large centers in the region are early adopters of robotic-assisted and image-integrated platforms, often leveraging local manufacturing partnerships to reduce cost and accelerate deployment. Across Asia-Pacific, growth is driven by demographic shifts, rising procedural volumes for oncology and cardiovascular interventions, and an increasing emphasis on reducing peri-procedural morbidity through minimally invasive approaches. Each regional cluster therefore requires tailored product configurations, service models, and clinical evidence strategies to align with local procurement norms and care delivery priorities.

Actionable corporate intelligence on how competitive moves, software-centric strategies, and service innovations are redefining leadership and partnership opportunities in image-guided therapy

Competitive dynamics in the image-guided therapy space are increasingly defined by end-to-end value propositions that combine imaging hardware, navigation platforms, and software-driven workflow orchestration. Leading companies are expanding portfolios through targeted partnerships, acquisitions, and co-development agreements that accelerate integration between imaging modalities and navigation suites. These moves are intended to reduce clinical friction and provide clearer upgrade paths for health systems seeking interoperable, scalable solutions.

A pronounced shift toward software-defined differentiation is reshaping product roadmaps. Firms investing in image processing algorithms, enhanced visualization, and intuitive navigation interfaces are improving clinician acceptance and reducing training burdens. Service offerings-ranging from preventative maintenance and remote diagnostics to embedded procedural coaching and outcome analytics-are becoming core revenue drivers and customer retention mechanisms. Organizations that excel at delivering predictable uptime and clinically meaningful analytics are building stronger long-term contracts and deeper clinical partnerships.

Strategic players are also addressing reimbursement and evidence gaps by sponsoring clinical studies, real-world evidence programs, and collaborative registries that document outcomes across procedural settings. This evidence not only supports clinical adoption but also strengthens value narratives during contracting negotiations with payers and integrated delivery networks. Finally, innovation in consumables and accessory design-focused on disposability, sterility workflows, and cost-effectiveness-remains a fast-moving front where relatively smaller players can achieve rapid market traction through targeted clinical use cases.

Practical, high-impact recommendations for product, clinical evidence, supply chain, and commercial strategies that executives can implement to accelerate adoption and long-term growth

Industry leaders should prioritize a set of coordinated actions to capture clinical and commercial advantage in image-guided therapy systems. First, align product roadmaps to deliver modular interoperability across imaging modalities and navigation platforms, enabling customers to scale capabilities without full-system replacement. Designing products for incremental upgrades reduces procurement friction and broadens addressable use cases across hospitals, ambulatory centers, and specialty clinics.

Second, invest in clinical evidence programs that tie procedural improvements to concrete patient outcomes and operational metrics. Collaborations with high-volume clinical centers, registries, and specialty societies can accelerate the evidence generation process and strengthen reimbursement conversations. Third, expand services and software subscriptions to shift commercial models toward predictable recurring revenue while delivering tangible operational improvements for care providers, including reduced downtime, streamlined workflows, and data-driven clinical decision support.

Fourth, strengthen supply chain resilience through regional manufacturing, dual sourcing, and strategic inventory partnerships to mitigate tariff impacts and component scarcity. Proactively sharing contingency plans with large customers builds trust and reduces the risk of contract disruptions. Fifth, tailor regional go-to-market strategies that reflect local procurement behaviors and clinical practice patterns; a one-size-fits-all approach will undermine adoption in diverse healthcare systems. Finally, prioritize user-centered design and clinician training programs to accelerate proficiency and reduce the learning curve, which in turn accelerates utilization and demonstrates faster return on procedural efficiency.

Robust and transparent research methodology combining primary clinician and procurement interviews with secondary validation and multi-source triangulation to ensure actionable findings

The research methodology underpinning these insights combined structured primary research with comprehensive secondary validation and rigorous triangulation. Primary inputs included in-depth interviews with interventional clinicians across specialties such as cardiology, neurology, oncology, and orthopedics, procurement leaders from hospitals and ambulatory surgical centers, and technical managers responsible for imaging and navigation system deployments. These conversations provided firsthand perspectives on clinical requirements, procurement constraints, and operational performance considerations.

Secondary research synthesized regulatory guidances, clinical literature, technology whitepapers, and publicly available product documentation to contextualize primary inputs and verify technology capabilities. Data triangulation was applied to reconcile variations across sources and to identify consensus views on adoption drivers and barriers. Where applicable, scenario analysis was used to explore the implications of policy shifts, component availability, and reimbursement changes on procurement behavior and deployment timelines.

Quality control procedures included cross-validation of respondent inputs, internal peer reviews, and expert panel discussions to ensure that conclusions were robust and actionable. Segmentation frameworks were mapped against clinical workflows and procurement archetypes to ensure relevance for both strategic planning and tactical commercialization. The resulting methodology supports reproducible insights that can be applied to tailored assessments for product development, go-to-market planning, and investment evaluation.

Concise conclusion emphasizing the imperative for integrated technical, clinical, and commercial strategies to realize the promise of image-guided therapy across care settings

The trajectory for image-guided therapy systems is clear: clinical demand for precision, operational efficiency, and patient-centered outcomes will continue to drive adoption of integrated imaging, navigation, and software platforms. Successful suppliers will be those that can combine clinical evidence, flexible commercial models, resilient supply chains, and user-centric designs to lower the barriers to adoption across diverse care settings. The interplay of technological innovation and shifting procurement behaviors requires agile strategies that balance immediate operational needs with long-term platform development.

Tariff-related pressures and regional investment patterns underscore the importance of localized strategies and supplier diversification. Companies that proactively adapt manufacturing footprints, offer modular upgrade pathways, and align clinical evidence efforts with payer and provider priorities will be better positioned to sustain growth and secure meaningful clinical partnerships. Ultimately, the most successful organizations will translate technical differentiation into measurable clinical and economic value, enabling providers to deliver safer, more efficient interventions while strengthening their own commercial and strategic positions in a rapidly evolving healthcare landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Image-guided Therapy System Market, by Product

  • 8.1. Hardware
  • 8.2. Services
  • 8.3. Software
    • 8.3.1. Image Processing Software
    • 8.3.2. Navigation Software
    • 8.3.3. Workflow Management Software

9. Image-guided Therapy System Market, by Imaging Modality

  • 9.1. Cone Beam Ct
  • 9.2. Ct
  • 9.3. Fluoroscopy
  • 9.4. Mri
  • 9.5. Ultrasound

10. Image-guided Therapy System Market, by Component

  • 10.1. Accessories
  • 10.2. Consumables
  • 10.3. Imaging Equipment
  • 10.4. Navigation System

11. Image-guided Therapy System Market, by Therapy Type

  • 11.1. Minimally Invasive
    • 11.1.1. Endoscopic
    • 11.1.2. Laparoscopic
    • 11.1.3. Robotic
  • 11.2. Open Surgery

12. Image-guided Therapy System Market, by Application

  • 12.1. Cardiovascular
  • 12.2. Gastroenterology
  • 12.3. Neurology
  • 12.4. Oncology
  • 12.5. Orthopedics
  • 12.6. Urology

13. Image-guided Therapy System Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Hospitals
  • 13.3. Imaging Centers
  • 13.4. Specialty Clinics

14. Image-guided Therapy System Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Image-guided Therapy System Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Image-guided Therapy System Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Image-guided Therapy System Market

18. China Image-guided Therapy System Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Accuray, Inc.
  • 19.6. Analogic Corporation
  • 19.7. Brainlab AG
  • 19.8. Canon Medical Systems Corporation
  • 19.9. Cook Medical, Inc.
  • 19.10. Elekta AB
  • 19.11. GE HealthCare Technologies Inc.
  • 19.12. Hologic, Inc.
  • 19.13. IMRIS, Inc.
  • 19.14. Johnson & Johnson
  • 19.15. Konica Minolta, Inc.
  • 19.16. Koninklijke Philips N.V.
  • 19.17. Medtronic plc
  • 19.18. Olympus Corporation
  • 19.19. RaySearch Laboratories AB
  • 19.20. Shimadzu Corporation
  • 19.21. Siemens Healthineers AG
  • 19.22. Smith & Nephew plc
  • 19.23. Stryker Corporation
  • 19.24. Terumo Corporation
  • 19.25. Varian Medical Systems, Inc.
  • 19.26. Ziehm Imaging GmbH
  • 19.27. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGE PROCESSING SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGE PROCESSING SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGE PROCESSING SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONE BEAM CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONE BEAM CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONE BEAM CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY FLUOROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY FLUOROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY FLUOROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NAVIGATION SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ROBOTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ROBOTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ROBOTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY GASTROENTEROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY GASTROENTEROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY UROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY UROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY UROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GCC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 185. GCC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 188. GCC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. GCC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. GCC IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 212. G7 IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 215. G7 IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 217. G7 IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. G7 IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. NATO IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. NATO IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 221. NATO IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 224. NATO IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. NATO IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. NATO IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA IMAGE-GUIDED THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)